目的探讨IQGAP2在乳腺癌中的表达,沉默IQGAP2对三阴型乳腺癌(triple-negative breast cancer,TNBC)细胞体外增殖、迁移及侵袭的影响。方法使用UALCAN数据库分析IQGAP2在正常乳腺组织和不同分子亚型乳腺癌中的表达。选用siRNA干扰TNBC细...目的探讨IQGAP2在乳腺癌中的表达,沉默IQGAP2对三阴型乳腺癌(triple-negative breast cancer,TNBC)细胞体外增殖、迁移及侵袭的影响。方法使用UALCAN数据库分析IQGAP2在正常乳腺组织和不同分子亚型乳腺癌中的表达。选用siRNA干扰TNBC细胞株SUM159中IQGAP2的表达,采用qRT-PCR、Western blot检测干扰效率。应用MTT法检测细胞增殖能力的改变;Transwell小室实验检测细胞迁移以及侵袭能力的改变。结果IQGAP2在乳腺癌组织中表达显著低于正常乳腺组织,且在TNBC中的表达水平最低(P<0.01)。转染siIQGAP2后,SUM159细胞中IQGAP2的表达显著下调(P<0.01)。与对照组相比,沉默IQGAP2的表达可促进乳腺癌细胞系SUM159的增殖、迁移以及侵袭能力(P<0.01)。结论IQGAP2可能参与TNBC生物学行为的调控。展开更多
Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six...Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six genes(ADAM8,IQGAP2,SLC16A12,PYCR1,TOX3,and LRRC19)involved in lipid metabolism and immune response.These genes are differentially expressed in ccRCC and are associated with tumor progression and patient survival.The LIS shows potential for improving diagnosis,prognosis evaluation,and identifying therapeutic targets in ccRCC.Although promising,further validation and clinical standardization are needed.展开更多
文摘目的探讨IQGAP2在乳腺癌中的表达,沉默IQGAP2对三阴型乳腺癌(triple-negative breast cancer,TNBC)细胞体外增殖、迁移及侵袭的影响。方法使用UALCAN数据库分析IQGAP2在正常乳腺组织和不同分子亚型乳腺癌中的表达。选用siRNA干扰TNBC细胞株SUM159中IQGAP2的表达,采用qRT-PCR、Western blot检测干扰效率。应用MTT法检测细胞增殖能力的改变;Transwell小室实验检测细胞迁移以及侵袭能力的改变。结果IQGAP2在乳腺癌组织中表达显著低于正常乳腺组织,且在TNBC中的表达水平最低(P<0.01)。转染siIQGAP2后,SUM159细胞中IQGAP2的表达显著下调(P<0.01)。与对照组相比,沉默IQGAP2的表达可促进乳腺癌细胞系SUM159的增殖、迁移以及侵袭能力(P<0.01)。结论IQGAP2可能参与TNBC生物学行为的调控。
文摘Clear cell renal cell carcinoma(ccRCC)is the most common and aggressive subtype of renal cancer.Despite advances in treatment,its prognosis remains poor.In this study,we developed a lipid immune score(LIS)based on six genes(ADAM8,IQGAP2,SLC16A12,PYCR1,TOX3,and LRRC19)involved in lipid metabolism and immune response.These genes are differentially expressed in ccRCC and are associated with tumor progression and patient survival.The LIS shows potential for improving diagnosis,prognosis evaluation,and identifying therapeutic targets in ccRCC.Although promising,further validation and clinical standardization are needed.
